Immunotherapy resistance and strategies in malignant pleural mesothelioma

Our plain-English summary of Immunotherapy resistance and strategies in malignant pleural mesothelioma, by W. Xia, Y. Zhang, J. Zhao, et al (Cancer Drug Resistance, 2026).

The study

• Authors: W. Xia, Y. Zhang, J. Zhao, X. Tan, S. Ju, W. Zou, C. Chen, C. Li, Y. Xu, Y. Peng, S. Li
• Journal: Cancer Drug Resistance
• Published: 2026;9:9
• Type of article: Review
• Cited by: 1 article, as counted by NIH iCite
• Read it: PubMed · Publisher · Free full text

Abstract

Malignant pleural mesothelioma (MPM) remains one of the most aggressive thoracic malignancies, characterized by profound resistance to conventional modalities such as surgery, chemotherapy, and radiotherapy, resulting in persistently poor survival outcomes. The advent of immune checkpoint inhibitors (ICIs) has fundamentally reshaped the therapeutic landscape of MPM. Notably, dual programmed cell death protein 1 (PD-1)/cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) blockade has demonstrated superior efficacy over monotherapy in multiple phase I/II trials and has been established as a novel first-line standard of care. Nevertheless, the high incidence of resistance continues to pose a major clinical challenge. This therapeutic bottleneck is largely attributed to the unique biology of MPM, including a profoundly immunosuppressive tumor microenvironment, aberrantly activated signaling pathways, and complex metabolic reprogramming, which together form a multilayered defense network against immune attack. In response to this intricate resistance architecture, recent research efforts have increasingly focused on the development of precision combination strategies. By rationally integrating ICIs with anti-angiogenic agents, chemotherapy, metabolic modulators, and next-generation cellular immunotherapies [e.g., chimeric antigen receptor T cells (CAR-T), chimeric antigen receptor-natural killer (CAR-NK)], these approaches aim to dismantle immune evasion barriers and reinvigorate antitumor immunity. Concurrently, the discovery of novel biomarkers and their integration with multi-omics data are enabling more precise patient stratification, signaling the advent of an era of personalized immunotherapy for MPM. This review provides a systematic synthesis of the latest clinical advances and fundamental breakthroughs in MPM immunotherapy, with a particular focus on dissecting the multifactorial mechanisms underlying therapeutic resistance. Its core contribution lies in constructing a forward-looking framework for next-generation treatment strategies. It critically evaluates the translational potential of emerging approaches, including arginine deprivation therapy for argininosuccinate synthase 1 (ASS1)-deficient tumors, CAR-T cells, T-cell receptor fusion constructs, and oncolytic virotherapy. By integrating these innovative modalities with biomarker-guided patient selection, this review delineates a roadmap for transitioning MPM management from empirical therapy toward precision immuno-oncology, with the ultimate goal of achieving durable disease control in this challenging malignancy.

© The Author(s) 2026.

In plain English

This article was a review, not an original study. The authors summarized published clinical trials and laboratory research on immunotherapy for malignant pleural mesothelioma. They focused on why many tumors resist immune checkpoint drugs and on strategies being tested to overcome that resistance. As background, they stated that asbestos exposure is responsible for nearly 80% of these cancers. Among the trials they described, CheckMate 743 reported a median overall survival of 18.1 versus 14.1 months for nivolumab plus ipilimumab compared with platinum-pemetrexed chemotherapy. In BEAT-meso, adding atezolizumab to bevacizumab and chemotherapy gave a statistically significant improvement in median progression-free survival (9.2 versus 7.6 months). The overall survival difference in that trial (20.5 versus 18.1 months) was not statistically significant. The authors also reviewed arginine-deprivation therapy, CAR-T and related cell therapies, dendritic-cell vaccines, oncolytic viruses and possible biomarkers, and noted that PD-L1 showed inconsistent predictive value. They cautioned that most combination strategies are still at an early stage of clinical development. They concluded that overcoming resistance requires disrupting multiple suppressive pathways at once. Some trial figures differ between the article's tables and its text.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: Narrative review of published clinical trials and preclinical research on immunotherapy and resistance mechanisms in malignant pleural mesothelioma
• Who was studied: No study population of its own. The article reviewed trials in patients with malignant pleural mesothelioma (MPM), including representative trials from 2020-2025, plus laboratory and preclinical studies.
• Exposure: Not an exposure study. The subject is treatment: immune checkpoint inhibitors alone or combined with chemotherapy, anti-angiogenic drugs, arginine deprivation (ADI-PEG20), CAR-T and related cell therapies, dendritic-cell vaccines and oncolytic viruses. Asbestos is mentioned only as background, as the main cause of MPM; no fiber types are discussed.
• Main results:
  • CheckMate 743 (as described by the review): nivolumab plus ipilimumab versus platinum-pemetrexed in first-line treatment gave a median overall survival of 18.1 vs. 14.1 months (hazard ratio about 0.73).
  • CheckMate 743, non-epithelioid subgroup (as described by the review): overall survival 18.1 vs. 8.8 months, hazard ratio 0.46. The authors called histologic subtype the most clinically actionable biomarker to date.
  • KEYNOTE-483 (as described by the review): in 539 patients with previously untreated, unresectable MPM, pembrolizumab plus platinum-pemetrexed versus chemotherapy alone gave a median overall survival of 17.3 vs. 16.1 months (hazard ratio 0.79).
  • BEAT-meso (as described by the review): in 400 patients, median progression-free survival was 9.2 months with atezolizumab plus bevacizumab and chemotherapy versus 7.6 months with bevacizumab plus chemotherapy (hazard ratio 0.72).
  • BEAT-meso overall survival (as described by the review): 20.5 vs. 18.1 months, p = 0.14, not statistically significant. In the prespecified non-epithelioid subgroup the hazard ratio for overall survival was 0.51.
  • ATOMIC-Meso (as described by the review): in 249 patients described as having ASS1-deficient MPM, pegargiminase (ADI-PEG20) plus chemotherapy gave a median overall survival of 9.3 vs. 7.7 months (hazard ratio 0.71). Median progression-free survival was 6.2 vs. 5.6 months in the text.
  • Mesothelin-directed CAR-T studies (as described by the review) showed objective response rates of 12%-26%. In an 11-patient first-in-human study of an armored CAR-T (NAC-T), the objective response rate was 63.6%. The authors noted that the armored CAR-T findings come from small, non-randomized cohorts.
  • The review found that PD-L1 expression has inconsistent value for predicting response to immunotherapy in MPM.
• The authors' conclusion: The authors concluded that overcoming immunotherapy resistance in MPM requires disrupting several suppressive pathways at the same time rather than a single therapeutic axis. They presented linking mechanism, target and treatment strategy as a translational roadmap.
• Limitations the authors state:
  • Most combination strategies are still in early-phase clinical development. They often rely on small, non-randomized cohorts without biomarker-driven patient selection.
  • Reported response signals may reflect selection bias rather than genuine synergy between treatments.
  • The pivotal trials were conducted mainly in Western cohorts.

Topics

Medical terms in this study, explained in our Lexicon: Immunotherapy, Pleural Mesothelioma, Chemotherapy, checkpoint inhibitors, CTLA-4, Tumor Microenvironment, Discovery, Biomarker.

Related studies

• Malignant mesothelioma resistance to apoptosis: recent discoveries and their implication for effective therapeutic strategies — F. Villanova, A. Procopio, et al. (2008)
• Immunotherapy strategies for mesothelioma - the role of tumor specific neoantigens in a new era of precision medicine — L. Ye, S. Ma, et al. (2019)
• Advances in Immunotherapy for Malignant Pleural Mesothelioma: From Emerging Strategies to Translational Insights — R. López-Castro, Á. Fuentes-Martín, et al. (2024)
• Immunotherapy for Treatment of Pleural Mesothelioma: Current and Emerging Therapeutic Strategies — L. Chiec, D.S. Bruno (2024)
• The Immune Microenvironment in Mesothelioma: Mechanisms of Resistance to Immunotherapy — G.J. Chu, N. van Zandwijk, et al. (2019)
• Exposing Hidden Targets: Combining epigenetic and immunotherapy to overcome cancer resistance — K. Olino, T. Park, et al. (2020)

Browse return to medical research.